EpiFix (allograft system)

2021: Launch of transplant production to treat complications of diabetes mellitus that can lead to leg amputation

At the end of February 2021, Medtech Company MiMedx introduced a EpiFix allotransplantation system for the treatment of diabetic foot ulcers. Transplants are made from donor placental tissues obtained from the mother during caesarean section. These tissues undergo a patented treatment and cleaning procedure that results in a dehydrated graft. It can be stored at room temperature for a long time and used as required.

EpiFix (allograft system)

Trophic foot and shin ulcers are relatively common in diabetic patients and appear in 15% of such patients. These ulcers are usually very poorly treatable and often accompanied by various complications, such as infection, requiring hospitalization. The allograft EpiFix protects the wound site and promotes the healing process, with a number of studies showing that the EpiFix technique is more effective than other technologies for healing trophic ulcers in diabetes mellitus. It is known that EpiFix creates a semipermeable protective barrier that supports the healing cascade and protects the wound bed, promoting the development of granulation tissue in acute and chronic wounds.

The allograft is EpiFix obtained from placental donor tissues after a planned caesarean section, wherein the transplant treatment is performed in such a way as to preserve the extracellular matrix and more than 300 regulatory proteins, but remove blood contaminants. As a result, an easy to use product with a shelf life of five years is formed, which can be stored at room temperature. To ensure safety, the finished product is sterilized. The allograft is EpiFix available in various configurations: leaf, mesh and crushed, as well as in various sizes to reduce tissue loss.^[1]

Notes